Chlamydia Market Report 2026

The chlamydia market size has grown strongly in recent years. It will grow from $3.23 billion in 2025 to $3.51 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to increasing prevalence of sexually transmitted infections, expansion of public health screening initiatives, improved access to diagnostic laboratories, rising awareness of reproductive health, availability of antibiotic treatment options.

The chlamydia market size is expected to see strong growth in the next few years. It will grow to $4.86 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increasing demand for point-of-care diagnostics, rising focus on preventive sexual healthcare, expansion of digital health screening platforms, growing investments in diagnostic innovation, increasing government-led sti control programs. Major trends in the forecast period include increasing adoption of rapid chlamydia testing methods, rising use of naat-based diagnostic techniques, growing focus on early sti screening programs, expansion of home-based testing solutions, enhanced awareness of asymptomatic infections.

The rising prevalence of sexually transmitted diseases is anticipated to drive the growth of the chlamydia market in the coming years. Sexually transmitted diseases (STDs) are infections transmitted through sexual contact and include conditions such as chlamydia, gonorrhea, and HIV. The increase in STD cases is linked to factors such as reduced condom usage, insufficient awareness, limited access to healthcare services, and the widespread use of dating applications that facilitate multiple sexual partnerships. Chlamydia treatment plays a key role in limiting the spread of STDs by clearing the infection, preventing long-term complications, and reducing the risk of transmission to sexual partners. For instance, in October 2025, according to the Minority HIV/AIDS Fund (MHAF), a US-based government agency, an estimated 39.9 million people worldwide were living with HIV in 2023, including 38.6 million adults and 1.4 million children, reflecting a continued global burden. Therefore, the increasing prevalence of sexually transmitted diseases is fueling the growth of the chlamydia market.

Major companies operating in the chlamydia market are emphasizing the development of innovative solutions, such as the expansion of point-of-care molecular diagnostics, to enable faster and more accurate onsite detection and support timely treatment decisions. Point-of-care molecular diagnostics expansion refers to the increased adoption of rapid, onsite molecular testing solutions that allow immediate identification of infections such as chlamydia without dependence on centralized laboratory infrastructure. For instance, in January 2025, F. Hoffmann-La Roche AG, a Switzerland-based healthcare company, received FDA 510(k) clearance along with a CLIA waiver for its cobas liat molecular tests, which are designed for point-of-care diagnosis of sexually transmitted infections. These tests include multiplex assay panels capable of detecting and differentiating multiple STIs, including chlamydia, gonorrhea, and Mycoplasma genitalium, from a single patient sample, delivering results in 20 minutes or less.

In December 2023, Imaware, a US-based digital health company, acquired the consumer testing business of Binx Health for an undisclosed amount. Through this acquisition, Imaware aims to reinforce its leadership in STI screening, broaden its consumer diagnostic offerings, improve access to at-home testing solutions, and accelerate growth within the sexual health market. Binx Health is a US-based healthcare company that specializes in providing at-home testing solutions for sexually transmitted infections.

Major companies operating in the chlamydia market are Siemens Healthineers, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, Hologic Inc, Quidel Corporation, Bio-Rad Laboratories Inc, Ortho Clinical Diagnostics, DiaSorin SpA, Eiken Chemical Co Ltd, MedMira Inc, GenMark Diagnostics Inc, ACON Laboratories Inc, Biocartis Group NV, Inova Diagnostics Inc, Trinity Biotech Plc, Seegene Inc, Qiagen NV, Binx Health Inc, Chembio Diagnostics Inc, Visby Medical Inc.

North America was the largest region in the chlamydia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chlamydia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chlamydia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the chlamydia market by increasing costs of imported diagnostic kits, laboratory reagents, testing instruments, and pharmaceutical ingredients used in treatment. Hospitals and diagnostic centers in North America and Europe are most affected due to reliance on imported diagnostic technologies, while Asia-Pacific faces higher costs for test kit manufacturing and distribution. These tariffs are raising testing expenses and slowing screening expansion. However, they are also encouraging domestic production of diagnostic kits and regional manufacturing of affordable testing solutions.

The chlamydia market research report is one of a series of new reports that provides chlamydia market statistics, including chlamydia industry global market size, regional shares, competitors with a chlamydia market share, detailed chlamydia market segments, market trends and opportunities, and any further data you may need to thrive in the chlamydia industry. This chlamydia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chlamydia is a widespread sexually transmitted infection (STI) caused by Chlamydia trachomatis. It often presents without noticeable symptoms but can lead to serious complications such as infertility and pelvic inflammatory disease if left untreated. The infection is readily treatable with antibiotics, and prevention strategies include practicing safe sex and undergoing regular STI screening.

The main types of tests used to diagnose chlamydia include culture tests, nucleic acid amplification tests (NAAT), direct fluorescent antibody tests, serology tests, and others. Culture tests involve growing bacteria from a collected sample in a laboratory to detect infections such as chlamydia. A healthcare provider collects a sample, typically from the cervix, urethra, or throat, and places it in a specialized culture medium. The growth of chlamydia bacteria confirms the presence of infection. Although culture tests are reliable, they generally require more time to produce results compared to other diagnostic methods. Treatments are administered through routes such as oral, injectable, and others, and are provided by end users including hospitals, diagnostic centers, ambulatory surgical centers, and other healthcare settings.

The chlamydia market includes revenues earned by entities by entities by providing services such as diagnostic testing services, screening programs, treatment services, telehealth and online consultations and related products such as lateral flow assays, enzyme-linked immunosorbent assay (Elisa) kits, multiplex STI panels, macrolides, and fluoroquinolones. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.